Enterprise Therapeutics, a biopharmaceutical company specialising in respiratory disease, has appointed Dr Renu Gupta as Chief Medical Officer (CMO) and Dr Janet Hammond as a Non-Executive Director.
Dr Gupta
Dr Gupta is a physician-scientist with more than 20 years of experience as a CMO — most recently at Promedior, a member of the Roche Group.
She has held various roles within research and development, executive management and as a Board member; including at Global Bio-Pharma, Corbus Pharmaceuticals, Breath Therapeutics, Insmed, Novartis and Bristol-Myers Squibb (BMS).
Dr Gupta has been a key player in implementing regulatory and clinical strategies, as well as focusing on development pathways to advance targets in rare disease indications.
She received her bachelor and medical degrees from the University of Zambia and completed her medical and post-doctoral training at Albert Einstein Medical Center, the Wistar Institute of Anatomy and Biology, the Children's Hospital of Philadelphia, and the University of Pennsylvania.
Dr Hammond
Dr Hammond has more than 20 years’ experience in the pharmaceutical industry, during which time she has overseen the development and successful approval of several drugs.
She is currently Chief Development Officer at Atea Pharmaceuticals, a Boston-based biotech focused on the development of antiviral drugs for life-threatening infectious diseases.
Prior to joining Atea, Janet was Vice President and Head of Infectious Diseases and General Medicine at AbbVie and Senior Vice President and Global Head of Infectious Diseases at Hoffmann-la Roche.
She obtained her MD and PhD from the University of Cape Town where she specialised in Pulmonary/Critical Care Medicine, holds a Masters in Clinical Investigation from Johns Hopkins University, and carried out training in Infectious Diseases at Duke and Johns Hopkins Universities.
Dr John Ford, CEO, Enterprise Therapeutics, said: “We are delighted to welcome Renu as CMO and Janet to the Board. Renu’s successful track record in developing respiratory medicines will be a great asset to the team, while Janet’s extensive experience in driving late-stage clinical development programmes will be an invaluable addition to the Board.”
